MKGAF - Merger Arbitrage Mondays - 2 New Acquisitions At Huge Premiums
Merger activity remained unchanged last week with two new deals announced and seven deals closing.
Deal Statistics:
New Deals:
- The acquisition of Alder BioPharmaceuticals (ALDR) by H. Lundbeck A/S for $1.95 billion. Under the terms of the agreement, Alder stockholders will be offered an upfront payment for USD 18.00 per share in cash, along with one non-tradeable Contingent Value Right ((CVR)) that entitles them to an additional USD 2.00 per share upon approval of the migraine prevention drug eptinezumab by the European Medicines Agency ((EMA)), representing a total potential consideration of USD 20.00 per share.